Search

Your search keyword '"Chung, Nack‐Gyun"' showing total 468 results
Start Over Author "Chung, Nack‐Gyun"
468 results on '"Chung, Nack‐Gyun"'

5. Genomic insights into inherited bone marrow failure syndromes in a Korean population

Author

Lee, Jong‐Mi, primary, Kim, Hoon Seok, additional, Yoo, Jaeeun, additional, Lee, Jaewoong, additional, Ahn, Ari, additional, Cho, Hanwool, additional, Han, Eun Hee, additional, Jung, Jin, additional, Yoo, Jae Won, additional, Kim, Seongkoo, additional, Lee, Jae Wook, additional, Cho, Bin, additional, Chung, Nack‐Gyun, additional, Kim, Myungshin, additional, and Kim, Yonggoo, additional

Published
2024
Full Text
View/download PDF

6. Classification and prognostic stratification based on genomic features in myelodysplastic neoplasms, myeloproliferative neoplasms, and their overlapping conditions

Author

Kim, Myungshin, primary, Lee, Jong-Mi, additional, Lee, Ginkyeng, additional, Ahn, Ari, additional, Jung, Jin, additional, Kim, Yoo-Jin, additional, Park, Silvia, additional, Kwag, Daehun, additional, Lee, Sung-Eun, additional, Park, Sung-Soo, additional, Kim, Tong Yoon, additional, Cho, Bin, additional, Chung, Nack-Gyun, additional, Lee, Jae Wook, additional, Lee, Jae Won, additional, Jo, Suejung, additional, Kim, Yonggoo, additional, and Kim, Taeksang, additional

Published
2024
Full Text
View/download PDF

12. Repeated Infusions of Bone-Marrow-Derived Mesenchymal Stem Cells over 8 Weeks for Steroid-Refractory Chronic Graft-versus-Host Disease: A Prospective, Phase I/II Clinical Study.

Author

Kim, Nayoun, Min, Gi-June, Im, Keon-Il, Nam, Young-Sun, Song, Yunejin, Lee, Jun-Seok, Oh, Eun-Jee, Chung, Nack-Gyun, Jeon, Young-Woo, Lee, Jong Wook, and Cho, Seok-Goo

Subjects
MESENCHYMAL stem cells, GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, CHRONIC diseases, CHEMOKINE receptors, DEEP brain stimulation
Abstract

Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation associated with poor quality of life and increased morbidity and mortality. Currently, there are several approved treatments for patients who do not respond to steroids, such as ruxolitinib. Nevertheless, a significant proportion of patients fail second-line treatment, indicating the need for novel approaches. Mesenchymal stem cells (MSCs) have been considered a potential treatment approach for steroid-refractory cGVHD. To evaluate the safety and efficacy of repeated infusions of MSCs, we administered intravenous MSCs every two weeks to ten patients with severe steroid-refractory cGVHD in a prospective phase I clinical trial. Each patient received a total of four doses, with each dose containing 1 × 106 cells/kg body weight from the same donor and same passage. Patients were assessed for their response to treatment using the 2014 National Institutes of Health (NIH) response criteria during each visit. Ten patients with diverse organ involvement were enrolled, collectively undergoing 40 infusions as planned. Remarkably, the MSC infusions were well tolerated without severe adverse events. Eight weeks after the initial MSC infusion, all ten patients showed partial responses characterized by the amelioration of clinical symptoms and enhancement of their quality of life. The overall response rate was 60%, with a complete response rate of 20% and a partial response (PR) rate of 40% at the last follow-up. Overall survival was 80%, with a median follow-up of 381 days. Two patients died due to relapse of their primary disease. Immunological analyses revealed a reduction in inflammatory markers, including Suppression of Tumorigenicity 2 (ST2), C-X-C motif chemokine ligand (CXCL)10, and Secreted phosphoprotein 1(SPP1), following the MSC treatment. Repeated MSC infusions proved to be both feasible and safe, and they may be an effective salvage therapy in patients with steroid-refractory cGVHD. Further large-scale clinical studies with long-term follow-up are needed in the future to determine the role of MSCs in cGVHD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. A Study to Evaluate the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Patients with Pediatric Acute Lymphoblastic Leukemia Using Common Data Model-Based Real-World Data: A Retrospective Observational Study

Author

Choi, Yoona, Kim, Bo Kyung, Won, Jung-Hyun, Yoo, Jae Won, Choi, Wona, Jung, Surin, Kim, Jae Yoon, Choi, In Young, Chung, Nack-Gyun, Lee, Jae Wook, Choi, Jung Yoon, Kang, Hyoung Jin, and Lee, Howard

Subjects
REMISSION induction, INDUCTION chemotherapy, LYMPHOBLASTIC leukemia, CHILD patients, ACUTE leukemia
Abstract

Background: Rapid reduction of leukemic cells in the bone marrow during remission induction chemotherapy (RIC) can lead to significant complications such as tumor lysis syndrome (TLS). We investigated whether prephase steroid treatment before RIC could decrease TLS incidence and improve overall survival in pediatric patients with acute lymphoblastic leukemia (ALL). Methods: Data were extracted from the Common Data Model databases in two tertiary-care hospitals in Seoul, South Korea. Patients were classified into the treated or untreated group if they had received RIC with prephase steroid treatment ≥ 7 days before RIC in 2012– 2021 or not, respectively. Stabilized Inverse Probability of Treatment Weighting (sIPTW) was applied to ensure compatibility between the treated and untreated groups. The incidence of TLS within 14 days of starting RIC, overall survival (OS), and the incidence of adverse events of special interest were the primary endpoints. Multiple sensitivity analyses were performed. Results: Baseline characteristics were effectively balanced between the treated (n=308.4) and untreated (n=246.6) groups after sIPTW. Prephase steroid treatment was associated with a significant 88% reduction in the risk of TLS (OR 0.12, 95% CI: 0.03– 0.41). OS was numerically greater in the treated group than in the untreated group although the difference was not statistically significant (HR 0.64, 95% CI 0.25– 1.64). The treated group experienced significantly elevated risks for hyperbilirubinemia and hyperglycemia. The reduction in TLS risk by prephase steroid treatment was maintained in all of the sensitivity analyses. Conclusion: Prephase steroid treatment for ≥ 7 days before RIC in pediatric patients with ALL reduces the risk of TLS, while careful monitoring for toxicities is necessary. If adequately analyzed, real-world data can provide crucial effectiveness and safety information for proper management of pediatric patients with ALL, for whom prospective randomized studies may be difficult to perform for ethical and practical reasons. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Current Status and Physicians’ Perspectives of Childhood Cancer Survivorship in Korea: A Nationwide Survey of Pediatric Hematologists/Oncologists

Author

Lee, Ji Won, primary, Yeo, Yohwan, additional, Ju, Hee Young, additional, Cho, Hee Won, additional, Yoo, Keon Hee, additional, Sung, Ki Woong, additional, Koo, Hong Hoe, additional, Jeong, Su-Min, additional, Shin, Dong Wook, additional, Baek, Hee Jo, additional, Kook, Hoon, additional, Chung, Nack-Gyun, additional, Cho, Bin, additional, Kim, Young Ae, additional, Park, Hyeon Jin, additional, and Song, Yun-Mi, additional

Published
2023
Full Text
View/download PDF

50. Cytomegalovirus infection in seropositive unrelated cord blood recipients: a study of 349 Korean patients

Author

Park, Meerim, Lee, Young Ho, Lee, Soo Hyun, Yoo, Keon Hee, Sung, Ki Woong, Koo, Hong Hoe, Lee, Ji Won, Kang, Hyoung Jin, Park, Kyung Duk, Shin, Hee Young, Ahn, Hyo Seop, Lee, Jae Wook, Chung, Nack-Gyun, Cho, Bin, Kim, Hack-Ki, Koh, Kyung-Nam, Im, Ho Joon, Seo, Jong Jin, Baek, Hee Jo, Kook, Hoon, Hwang, Tai Ju, Lee, Jae Min, Hah, Jeong Ok, Lim, Yeon Jung, Park, Jun Eun, Lyu, Chuhl Joo, Lim, Young Tak, Chong, So Young, and Oh, Doyeun

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results